Alterity Therapeutics has received Fast Track designation from the FDA for its investigational drug, ATH434, as a potential treatment for Multiple System Atrophy (MSA), a neurodegenerative disease with no currently approved therapies. The Fast Track designation aims to expedite the development and review process for drugs that address unmet medical needs.
This designation follows the previously granted Orphan Drug Designation for ATH434, further highlighting the FDA’s recognition of its potential to be an innovative treatment for MSA. Alterity’s CEO, Dr. David Stamler, emphasized that this Fast Track status, along with recent scientific findings and positive Phase 2 clinical trial efficacy data, reinforces the promise of ATH434. He also noted that the designation will allow for more frequent interaction with the FDA, potentially accelerating the drug’s development and approval timeline, with the goal of bringing this treatment to patients sooner.